🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 128 of 173

  1. US 7718610

    Retrocyclins: antiviral and antimicrobial peptides

    Expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7718386

    Methods for the diagnosis of diabetes

    Expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7714014

    Targeting GLI proteins in human cancer by small molecules

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7714109

    Combinations and kits for cancer treatment using selected antibodies to aminophospholipids

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7713526

    Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7713939

    Illudin analogs useful as antitumor agents

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7713710

    Isolation and use of solid tumor stem cells

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7714007

    Method of alleviating chronic pain via peripheral glutaminase regulation

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7713721

    Methods and composition for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7713925

    Syndecans and angiogenesis

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7713934

    Thrombin peptide derivatives

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7713927

    Antimicrobial peptides

    Expires Mon May 06 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7709625

    Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy

    Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7709643

    Synthesis of sodium narcistatin and related compounds

    Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7709517

    Diarylhydantoin compounds

    Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7709456

    Modulation of gene expression by oligomers targeted to chromosomal DNA

    Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7709190

    Influenza A virus vaccines and inhibitors

    Expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7704701

    Diagnosis of prostate cancer with SPAS-1 cancer antigen

    Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7705164

    Metalloprotein inhibitors

    Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7704962

    Small oligonucleotides with anti-tumor activity

    Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7704558

    Cleaning article containing hydrophilic polymers

    Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7704985

    Treatment of irritable bowel syndrome and related bowel diseases

    Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7705188

    Structural modification of resveratrol: sodium resverastatin phosphate

    Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7704497

    Molecules with extended half-lives, compositions and uses thereof

    Expires Mon Apr 22 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7700127

    Method and compositions for preparing and delivering rumen protected lipids, other nutrients and medicaments

    Expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7700738

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    Expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7700651

    Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease

    Expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7700547

    Preventing airway mucus production by administration of EGF-R antagonists

    Expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7700134

    Prevention of cisplatin induced deafness

    Expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7696306

    Compositions and methods for preventing or treating cancer

    Expires Mon Apr 08 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7696227

    Small-molecule inhibitors of the androgen receptor

    Expires Mon Apr 08 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7696244

    Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof

    Expires Mon Apr 08 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7691965

    Helical synthetic peptides that stimulate cellular cholesterol efflux

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7691380

    Combined methods for tumor coagulation and tumor treatment

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7691567

    Methods and compositions relating to fortilin, an anti-apoptotic molecule, and modulators of fortilin

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7691607

    Expression system of NELL peptide

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7691832

    Methods of treatment of inflammatory diseases

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7691582

    Methods of secretory vimentin detection and modulation

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7691862

    Method and composition for treating periodontal disease

    Expires Mon Apr 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7687480

    Phosphonate compounds

    Expires Mon Mar 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7687506

    Selective serine/threonine kinase inhibitors

    Expires Mon Mar 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7687462

    Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition

    Expires Mon Mar 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7683046

    Benzodiazepine compositions for treating epidermal hyperplasia and related disorders

    Expires Mon Mar 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7683041

    Microgel particles for the delivery of bioactive materials

    Expires Mon Mar 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7682607

    Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas

    Expires Mon Mar 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7678824

    Methods for treatment with bucindolol based on genetic targeting

    Expires Mon Mar 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7678764

    Protein formulations for use at elevated temperatures

    Expires Mon Mar 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7678386

    Liposomes coated with selected antibodies that bind to aminophospholipids

    Expires Mon Mar 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.